A Reduced Carbohydrate Diet Intervention for Polycystic Ovary Syndrome (PCOS)
NCT ID: NCT01028989
Last Updated: 2013-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
23 participants
INTERVENTIONAL
2009-12-31
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS
NCT01482286
Time Restricted Eating for the Treatment of PCOS
NCT05629858
Insulin Resistance Before and During Pregnancy in Women With Polycystic Ovary Syndrome
NCT01475565
Insulin and the Polycystic Ovary Syndrome--Weight Reduction Study
NCT00436865
Protein and Polycystic Ovary Syndrome (PCOS)
NCT07158723
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Specific Aim of this proposal is to determine if a lower GL diet intervention is more effective than a standard (STD) diet in improving reproductive and metabolic outcomes of women with PCOS (both normal-weight and overweight/obese). We hypothesize that, in the absence of weight change, the lower GL diet will be more effective than the STD diet in decreasing insulin secretion, increasing insulin sensitivity, decreasing free T, decreasing fat from metabolically harmful sites, decreasing inflammation, and improving menstrual cyclicity and ovulation. Further, the lower GL diet will increase perceived fullness and decrease hunger, effects mediated via gut hormones.
Development of a diet that optimizes reproductive and metabolic health among women with PCOS will reduce reliance on pharmacologic treatments and improve quality of life, even in the absence of weight loss. This project is novel in being the first to conduct a highly controlled nutrition intervention in non-obese women with PCOS under weight stable conditions, utilizing robust measures of insulin secretion and action, fat distribution, inflammation, hunger/fullness, the gut hormone profile, and reproductive function. The results from this study can be used as a starting point from which to explore optimal diets for overweight women with PCOS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Reduced Glycemic Load Diet
36-40% fat; 40-42% carbohydrate; 18-22% protein
Glycemic Load \<=46 per 1000 calories
Reduced Glycemic Load Diet
36-40% fat; 40-42% carbohydrate; 18-22% protein
Glycemic Load \<=46 per 1000 calories
Standard Diet
25-27% fat; 55-57% carbohydrate; 18-22% protein
Glycemic Load \>=77 per 1000 calories
Standard Diet
25-27% fat; 55-57% carbohydrate; 18-22% protein
Glycemic Load \>=77 per 1000 calories
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Reduced Glycemic Load Diet
36-40% fat; 40-42% carbohydrate; 18-22% protein
Glycemic Load \<=46 per 1000 calories
Standard Diet
25-27% fat; 55-57% carbohydrate; 18-22% protein
Glycemic Load \>=77 per 1000 calories
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index 18.5-35 kg/m2
Exclusion Criteria
* Type 1 or 2 diabetes
* Self-reported claustrophobia
* Androgenic tumors or adrenal hyperplasia
* Hyperprolactinemia
* Implanted metal items
* Use of metformin or other diabetes drug
* Women using oral contraceptives will not be excluded, but will be required to discontinue use of these agents 3 months prior to testing.
19 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
University of Alabama at Birmingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Barbara Gower
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barbara A Gower, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham
Fernando Ovalle, MD
Role: PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham
G Wright Bates, MD
Role: PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Douglas CC, Gower BA, Darnell BE, Ovalle F, Oster RA, Azziz R. Role of diet in the treatment of polycystic ovary syndrome. Fertil Steril. 2006 Mar;85(3):679-88. doi: 10.1016/j.fertnstert.2005.08.045.
Hoover SE, Gower BA, Cedillo YE, Chandler-Laney PC, Deemer SE, Goss AM. Changes in Ghrelin and Glucagon following a Low Glycemic Load Diet in Women with PCOS. J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2151-e2161. doi: 10.1210/clinem/dgab028.
Gower BA, Goss AM. A lower-carbohydrate, higher-fat diet reduces abdominal and intermuscular fat and increases insulin sensitivity in adults at risk of type 2 diabetes. J Nutr. 2015 Jan;145(1):177S-83S. doi: 10.3945/jn.114.195065. Epub 2014 Dec 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F090407003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.